United States Copyrig.ht Office l 1brary ot Congress . 101 Independence A,enue SE · Washington, DC 20559-6000 • www.cop)right.gov
Richard A. Hennan, Esq. 30850 Telegraph, Suite 250 Bingham Fanns. M1 48025
March 16, 2017
Re: Second Request for Reconsideration for Refusal to Register 2015 EIDM Essentials List; Correspondence ID: 1-l GLHJER; SR # l -2061432731
Dear Mr. Herman:
The Review Board of the United States Copyright Office ( .. Board"') has considered EHlM' s second request for reconsideration of the Registration Program's refusal to register a text claim in the work titled ·'2015 EHIM Essentials List" ("Work"). After reviewing the application, deposit copy, and relevant correspondence, along with the arguments in the second request for reconsideration, the Board affirms the Registration Program· s denial of registration.
I. DESCRIPTION OF THE WORK
The Work is 636 pages of text consisting of several introductory paragraphs followed by schedules of pharmaceutical products organized in alphabetical order by state. The introductory paragraphs are identical to those included in the work titled ··EHL\1 ESSENTIALS LIST (STATE OF MJCHIGAN)," registered on December 18, 2014 under the registration number TXu 1-934-686. Within each state schedule, the pharmaceutical products are listed fi rst alphabetically according to type. For example, under the schedule for the State of Alabama, the first category is ··Analgesics - Nonsteroidal Anti-Inflammatory Drugs." Nineteen specific pharmaceutical products are listed under this category, not in alphabetical order. but according to some other methodology.
An excerpt of the Work is included in Appendix A.
II. ADMI ISTRA TIVE RECORD
On January 15, 2015, EHIM fi led an application to register a copyright claim in the Work. ln a July 27, 2015 letter, a Copyright Office registration specialist refused to register the claim, finding that ·'the material deposited represents less than the required minimum amount of original authorship on which to base a claim." Letter from Duke Latkovic, Senior Registration Specialist. to Richard Hennan (July 27. 2015).
Richard A. Herman, Esq. - 2 - March 16, 2017
In a letter dated October 7, 2015, EHIM requested that the Office reconsider its initial refusal to register the Work. Letter from Richard A. Herman to U.S. Copyright Office (Oct. 7, 2015) ("First Request") . After reviewing the Work in light of the points raised in the First Request, the Office re-evaluated the claims and again concluded that the Work "does not contain any new textual authorship to support a second copyright registration," noting that "the text contained in [the Work] was the same as the text registered in EHIM ESSENTIALS LIST (STATE OF MICHIGAN) ." Letter from Stephanie Mason, AttorneyAdvisor, to Richard Herman (Mar. 3, 2016).
In a letter dated May 31, 2016, EHIM requested that, pursuant to 37 C.F.R. § 202.5(c), the Office reconsider for a second time its refusal to register the Work. Letter from Richard A. Herman to U.S. Copyright Office (May 31, 2016) ("Second Request"). In that letter, EHIM admitted that ''the introductory text is, in fact, the same." Id at 1. However, EHIM argued that "a minimum amount of originality and creativity exists, apart from the introductory text, to support registration," and that "[w]hile certain information and facts may not be copyrightable, compilations containing such information/facts may still contain that amount of originality necessary for registration." Id at 2.
Ill. DISCUSSION
A. The Legal Framework: Originality
A work may be registered if it qualifies as an "original work[] of authorship fixed in any tangible medium of expression." 17 U.S.C. § 102(a). In this context, the term "original" consists of two components: independent creation and sufficient creativity. See Feist Pub! 'ns, Inc. v. Rural Tel. Serv. Co. , 499 U.S. 340, 345 (1991 ). First, the work must have been independently created by the author, i.e., not copied from another work. Id. Second, the work must possess sufficient creativity. Id. Only a modicum of creativity is necessary, but the Supreme Court has ruled that some works (such as the alphabetized telephone directory at issue in Feist) fail to meet even this low threshold. Id. The Court observed that "[a]s a constitutional matter, copyright protects only those constituent elements of a work that possess more than a de minimis quantum of creativity." Id. at 363. It further found that there can be no copyright in a work in which ''the creative spark is utterly lacking or so trivial as to be virtually nonexistent." Id. at 359.
The Office's regulations implement the longstanding requirement of originality set fo rth in the Copyright Act and described in the Feist decision. See, e.g., 37 C.F.R. § 202. l(a) (prohibiting registration of " [w]ords and short phrases such as names, titles, slogans; familiar symbols or designs; [and] mere variations of typographic ornamentation, lettering, or coloring"); id. § 202.l O(a) (stating ''to be acceptable as a pictorial, graphic, or sculptural work, the work must embody some creative authorship in its delineation or form"). Some combinations of common or standard design elements may contain sufficient creativity with respect to how they are juxtaposed or arranged to support a copyright. Nevertheless, not every combination or arrangement will be sufficient to meet thi s test. See Feist, 499 U.S. at 358 (finding the Copyright Act " implies that some ' ways' [ of selecting, coordinating, or
Richard A. Herman, Esq. -3- March 16, 2017
arranging uncopyrightable material] will trigger copyright, but that others will not"). A determination of copyrightability in the combination of standard design elements depends on whether the selection, coordination, or arrangement is done in such a way as to result in copyrightable authorship. Id; see also Atari Games Corp. v. Oman, 888 F.2d 878 (D.C. Cir. 1989).
A mere simplistic arrangement of non-protectable elements does not demonstrate the level of creativity necessary to warrant protection. For example, the United States District Court for the Southern District of New York upheld the Copyright Office's refusal to register simple designs consisting of two linked letter "C" shapes "facing each other in a mirrored relationship" and two unlinked letter "C" shapes "in a mirrored relationship and positioned perpendicular to the linked elements." Coach, Inc. v. Peters, 386 F. Supp. 2d 495, 496 (S.D.N.Y. 2005). Likewise, the Ninth Circuit has held that a glass sculpture of a jellyfish consisting of clear glass, an oblong shroud, bright colors, vertical orientation, and the stereotypical jellyfish form did not merit copyright protection. See Satava v. Lowry , 323 F.3d 805, 811 (9th Cir. 2003). The language in Satava is particularly instructive:
It is true, of course, that a combination of unprotectable elements may qual ify for copyright protection. But it is not true that any combination of unprotectable elements automatically qualifies for copyright protection. Our case law suggests, and we hold today, that a combination of unprotectable elements is eligible for copyright protection only if those elements are numerous enough and their selection and arrangement original enough that their combination constitutes an original work of authorship.
Id. (internal citations omitted).
B. Analysis of the Work
After carefully examining the Work and applying the legal standards discussed above, the Board finds that the Work does not contain the requisite separable authorship necessary to sustain a claim to copyright.
EHIM has already acknowledged that the introductory text on the first page of the Work is identical to that prefacing the work "EHIM ESSENTIALS LIST (ST A TE OF MICHIGAN)," registered on December 18, 2014 under registration number TXu 1-934-686. Therefore, the Board considers only the lists of pharmaceutical products on pages 2 through 636.
EHIM does not seek to register a copyright claim in the name of each pharmaceutical product, of course, but solely in the selection and arrangement of these product names. See Second Request at 2. It argues that the compilations of pharmaceutical product names are "original works of authorship, maintaining the requisite amount of creativity in and of themselves." Id. It is undisputed that uncopyrightable elements may be protectable if selected and combined " in a distinctive manner indicating some ingenuity." Atari Games Corp., 888 F.2d at 883. And EHIM correctly notes that "compilations containing ...
Richard A. Herman, Esq. -4- March 16, 2017
information/facts may still contain that amount of originality necessary for registration." Second Request at 2.
However, here the Board finds that the selection, coordination, and arrangement of the Work's basic elements----<)ategories of medications and names of medications-is insufficient to render the Work original. These are concededly unprotectable facts, and, as the Ninth Circuit stated in Satava, "a combination of unprotectable elements is eligible for copyright protection only if those elements are numerous enough and their selection and arrangement original enough that their combination constitutes an original work of authorship." 323 F.3d 805 at 811. Here, the alphabetical listing of states, within which are alphabetical listings of medication categories, with sub-categories also listed alphabetically, are arranged in as commonplace a manner as possible. EHIM states that "the compilation and selection of the medications were chosen by EHIM to be included, [and] the order in which they are placed was created by EHIM." Second Request at 2. However, EHIM does not demonstrate what it is about the compilation, selection, and order of placement of the medications that constitutes creative authorship. There is no indication that EHIM selected, based on any independent criteria, only certain medications to place in each sub-category, nor that the categories and sub-categories themselves are anything more than descriptive facts. While it is true that the medications are not listed within each sub-category in alphabetical order, EHIM presents no evidence that the order of listing embodies any creativity or is based on any organizing principle. Instead, the entire Work is merely a statement of the following fact, without more: EHIM's pharmacy benefits cover the drugs listed in the Work. See COMP£ :DIUM (THIRD) § 707 (listing facts as an example of a work that does not satisfy the requirements of section 102(a) of the Copyright Act).
Accordingly, the Board finds that the Work's selection, coordination, and arrangement of unprotectable facts and information do not demonstrate the creative authorship necessary for copyright registration.
IV. CONCLUSION
For the reasons stated herein, the Review Board of the United States Copyright Office affirms the refusal to register the copyright claim in the Work. Pursuant to 37 C.F.R. § 202.S(g), this decision constitutes final agency action in this matter.
BY: Chris Weston Copyright Office Review Board
Richard A. Herman, Esq. -5 - March 16, 2017
APPENDIX:
Excerpt (pages 1-10) of "2015 EHIM Essentials List"
• .... . -Effective Date : 1/ 1/ 2015
A pharmacy plan that utilizes an Out--0f-Pocket (OOP) maximum shall be calculated based on therapy classes that are considered Essential Health Benefits (EHBs) under healthcare law.
Only out--0f-pocket expenses for prescriptions that are included on this Essentials List AND covered within a group's plan design will accumulate towards the 2015 OOP Maximum. Medications that are not included in this list may be covered by the prescription program however the out--0f-pocket costs will not accumulate toward your out--0f-pocket maximum.
Please refer to the Prescription Benefit Handbook for a detailed description of your actual plan design & copay levels.
Some of the medications included in this list will be subject to your specific plan design and formulary requirements. Clinical management, such as Step Therapy, Prior Authorization, and/or Quantity Limits and may be utilized before a drug can be covered by your prescription program.
This list applies to FDA-approved generic drugs, even if those drugs are not specifically listed as generic at the lime of distribution.
This list is subject to change at any time without notice.
State {or Territory) : ALABAMA Effective Date : 1 / 1/ 2015
ALABAMA
ANALGESICS • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
IBUPROFEN DICLOFENAC SODIUM NABUMETONE SUUNDAC
NAPROXEN ETODOLAC OXAPROZIN DIFLUNISAL
MELO XI CAM INDOMETHACIN PIROXICAM FENOPROFEN
KETOPROFEN MEFENAMIC ACID TOLMETIN
'ANALGESICS - OPIOID ANALGESICS, LONG-ACTING MORPHINE SULFATE SR
!ANALGESICS· OPIOID ANALGESICS, SHORT-ACTING
TRAMADOL
!ANESTHETICS • LOCAL ANESTHETICS UDOCAINE CREAM UDOCAINE/PRILOCAINE UDOCAINE PATCH
DICLOFENAC POTASSIUM KETOROLAC SALSALATE FLURBIPROFEN
!ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS • ALCOHOL DETERRENTS/ ANn-CRAVJNG
DISULFIRAM CHANTIX CAMPRAL
!ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS • OPIOID ANTAGONISTS BUPRENORPHINE NALOXONE
!ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS • SMOKING CESSATION AGENTS
BUPROPION NICOTROL PATCH
!ANTIBACTERIALS • AMINOGLYCOSIDES GENTAMICIN TOBRAMYCIN AMIKACIN TOBI
KANAMYCIN
!ANTIBACTERIALS • ANnBACTERIALS, OTHER TRIMETHOPRIM NITROFURANTOIN
CHANTIX
NEOMYCIN PAROMOMYON
NITROFURANTOIN MACROCRYST ALS
CLINDAMYCIN HCL CLINDAMYCIN PHOSPHATE MUPIROCIN NEO/POLY/GRAMODIN TRIMETHOPRIM/POLYMYXJN B THERMAZENE VANDAZOLE METHENAMINE ZIANA (VELTIN)
!ANTIBACTERIALS - BETA·LACTAM, CEPHALOSPORINS
CEPHALEXIN CEFUROXIME CEFADROXIL CEFPROZIL CEFPODOXIME CEFACLOR CEDAX SUPRAX CEFOTETAN CEFOXITIN
!ANTIBACTERIALS - BETA-LACTAM, OTHER MEROPENEM INVANZ
!ANTIBACTERIALS- BETA-LACTAM, PENICILLINS PENIOLUN V AMOXICILLIN DICLOXACJWN PENIOLUN G OXACIWN PIPERACILLIN
!ANTIBACTERIALS - MACROLIDES AZITHROMYCIN ERYTHROMYCIN BASE
CLARITHROMYCIN
CEFAZOLIN CEFEPIME
AZACTAM
AMOXICIWN CLAVULANATE NAFCILLIN
ERYTHROMYCIN STEARATE
AK-TOB STREPTOMYCIN
METRONIDAZOLE
NEO/POL Y / BAC/HC BACITRACIN VANCOMYCIN
CEFDINIR CEFDITOREN PIVOXJL CEFTRIAXONE CEFTAZIDIME
AMPICILUN AMPICILUN/SULBACTAM
EYRTHROMCYIN ETHYLSUCCINATE
Tli1 documlrt n1 l'10 dlla n11o< inb1Nlion ccnlanod ii Hs '*>cl.moot ('1Mr!Nllon1 n - by EHi!. k contaN logat/ p:Mlogod CONlde,,tial nl propnetay nlonnalion - - P'"'*1Y al EltM Illa ,s ~mncilcloan l'rough ll!lJNffllffl(s} llldlor lilln11111roqoa• h roc,ponlto keep h lnlormallon conldenli& Tllelnlonnaion maync>1bo roproduood, chcl>sed, IIMCI and.a<,_ upon. 11- . or r, p-t _ ... pmrWltlln c:on.wt al EHJl,l nu lnlcrmaon is also mocxlod soiol\<"" .. ,..,.. and/or ..... dKlciz8d by EllM 1o ......... it "YO<J •• not h nll<ldod cec:ipiont. .... ncify EHIM and irMMdaloll' -----~t,o- ArryllUIJ1hariz»d 19produc:lion, disd>ol.n, 1COHS..,. atd/cr aclion11..a.nc.ontio lnlorm*"1 isA,cdy~ andmoyonitto EHlMtolegal and/or ..-...-anddnagos.
mm EHIM 02014 (800) 311-3446 www.eh1mrx.com
II
Print Date: December 24, 2014 Page 2 of 636
Ptt• '" , Int
State ( or Territory) : ALABAMA Effective Date: 1/1/2015
!ANnBACTERIALS - QUINOLONES
CIPROFLOXACIN LEVOFLOXACIN VIGAMOX ZYMAXID
!ANnBACTERIALS - SULFONAMIDES
SMO/TMP SODIUM SULFACETAMIDE
!ANnBACTERIALS - TETRACYCUNES
OFLOXACIN FACTIVE
SULFADIAZINE
AVELOX NOROXIN
TMP/POLYMYXIN
OOXYCYCUNE MINOCYCUNE TETRACYCLINE DEMECLOCYCUNE
!ANncoNVULSANTS - ANTICONVULSANTS, OTHER
LEVET1RACETAM BANZEL
!ANncoNVULSANTS - CALCIUM CHANNEL MODIFYING AGENTS
ZONISAMIDE ETHOSUXIMIDE L YRICA CELONTIN
!ANncoNVULSANTS - GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS
GABAPENTIN DIVALPROEX VALPROIC ACID PRIMIDONE TIAGIBINE
IANncoNVULSANTS-GLUTAMATE REDUONG AGENTS
LAMOTRIGINE TOPIRAMATE FELBAMATE
!ANnCONVULSANTS - SODIUM CHANNEL AGENTS
PHENYTOIN CARBAMAZEPINE OXCARBAZEPINE APTIOM EPITOL PEGANONE
!ANnDEMENTIA AGENTS - ANnDEMENTIA AGENTS, OTHER
ERGOLOID MESYLATES
IANTIDEMENTIA AGENTS - CHOUNESTERASE INHIBITORS
OONEPEZIL GALANTAMINE RIVASTIGMINE
IANTIDEMENTIA AGENTS - N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST
NAMENDA
ANTIDEPRESSANTS - ANTIDEPRESSANTS, OTHER
TRAZODONE BUPROPION MIRTAZAPINE NEFAZODONE MAPROTIUNE VII BRYD APLENZIN OLEPTRO
ANTIDEPRESSANTS - MONOAMINE OXIDASE INHIBITORS
PHENELZINE TRANYLCYPROMINE EM SAM MARPLAN
!ANTIDEPRESSANTS - SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS
FLUOXET1NE PAROXETINE SERTRAUNE CITALOPRAM VENLAFAXINE VIIBRYD
ESCITALOPRAM
!ANTIDEPRESSANTS - TRICYCUCS
AMITRIPTYUNE IMIPRAMINE DOXEPIN DESIPRAMINE AMOXAPINE
IANTIEMETICS - ANTIEMETICS, OTHER
DIPHENHYDRAMINE MECUZINE METOCLOPRAMIDE CYCUZJNE
EHIM 0 2014 (800) 311-3446
Print Date: December 24, 2014
TRIMETHOBENZAMIDE CESAMET
www.eh1mrx.com
FLUVOXAMINE
IMIPRAMINE PAMOATE CLOMIPRAMINE
PROCHLORPERAZINE DEXAMETHASONE
CYMBALTA
NORTRIPTYUNE PROTRIPTYUNE
PROMETHAZINE SCOPOLAMINE
Page 3 of636
state (or Territory) : ALABAMA Effective Date : 1/1/2015
!ANnEMETICS - EMETOGENIC THERAPY AD~UNCTs ONDANSETRON MECLIZINE ANZEMET EMEND
jANnFUNGALS - ANTIFUNGALS
FLUCONAZOLE CLOTRIMAZOLE SELENIUM SULF1DE CICLOPIROX ITRACONAZOLE JUBUA
NYSTATIN/TRIAMCINOLONE MICONAZOLf KETOCONAZOLE CLO TRIM/BET A METH NOXAFlL
jANnGOUT AGENTS - ANTIGOUT AGENTS
METOCLOPRAMIDE
TERB1NAF1NE TERCONAZOLE GRISEOFULVIN FLUCYTOSINE CANCIDAS
ALLOPURINOL COLCRYS PROBENECID PROBENECID/COLCHIONE
ANTI-INFLAMMATORY AGENTS - GLUCOCORnCOIDS
METHYLPREDNISOLONE
GRANISETRON
NYSTATIN ECONAZOLf UNDECYLfNIC ACID VORICONAZOLE AMPHOTERICIN B
ULORIC
[ANTI-INFLAMMATORY AGENTS - NONSTEROIDAL ANTI-INFLAMMATORY DRUGS DICLOFENAC POTASSIUM IBUPROFEN
DICLOFENAC SODIUM NABUMETONE SULINDAC
NAPROXEN ETODOLAC OXAPROZIN DIFLUNISAL
MELOXICAM INDOMETHACIN PIROXICAM FENOPROFEN TOLMETIN KETOPROFEN MEFENAMIC ACID
IANTIMIGRAINE AGENTS - ERGOT ALKALOIDS
DIHYDROERGOTAMINE ISOMETHEPTENE/DICHLORALP HENAZONE APAP
ANTIMIGRAINE AGENTS - PROPHYLACTIC
PROPRANOLOL TIMOLOL TOPIRAMATE
IANTIMIGRAINE AGENTS - SEROTONIN (5-HT) 1B/1D RECEPTOR AGONISTS
SUMATRIPTAN
ANTIMYASTHENIC AGENTS - PARASYMPATHOMIMEncs PYRIDOSTIGMINE GUANIDINE REGONOL
ANnMYCOBACTERIALS - ANnMYCOBACTERIALS, OTHER
DAPSONE MYCOBUTIN
!ANnMYCOBACTERIALS - ANTITUBERCULARS ISONIAZID RI FAM PIN PRimN ISONARIF/RIFAMATE SEROMYCIN TRECATOR
!ANnNEOPLASTics - ALKYLAnNG AGENTS CYCLOPHOSPHAMIDE DACARBAZINE MATULANE LEU KE RAN
!ANnNEOPLASTics - ANTIANGIOGENIC AGENTS
REVUMID THALOMID
!ANnNEOPLASTics - ANTIESTROGENS/MODIFIERS TAMOXIFEN FARESTON
ETHAMBUTOL CAPASTAT
CEENU ALKERAN
EMCYT
KETOROLAC SALSALATE FLURBIPROFEN
GUANFACINE
PYRAZINAMIDE RIFATER
IFOSFAMIDE
Tl'D-r<! tie dala 11'1!1« iri1:rma1ion a>ntainod in t,is daa.mont('lnlannaon') •• - by etlM. lcontains leg.a, pMllged. ccnlldenb.i and p<Ollriebry .....,,_ and/er -.r propertr ol EHJM 1h11 ,s ~ tom<iscl:>uo trcoq, q-,1(s)......,. - llar""*9 Ile recipient ID keep lho lnlamalian Clltlldenul. The-may not be,.,.- disdo...s, "* - rehd upoc,, in ,onolt, o, 11 pa1. wt,,,-,,. pn,r-ca,sentol EHIM. TNs lnlonnalion is aiso irllon<»cl solely 1or Ile rac,p,ent and/ar-. dlorized by EHIM ID,..... l Myou .. noltie inlonded r""l*"I, p..,.. nolily EHIM and ....-1y ~ sired 11'1!1«--deRoy he fnlormlbon. Airy-~ -..0. aocess, U10 a,o'o, adlon II rtbioe.., Ille lnlonNlli<rl is snctlypr,1-.i .wlmay- EltMID legalnllor equ,lablt,.,.....ndamages.
am EHIM 0 2014 (800) 31 1-3446 www.ehimrx.com
Print Date: December 24, 2014 Page4 of636
jANnNEOPLASTICS - ANnMETABOUTES
HYDROXYUREA MERCAPTOPURINE
[ANnNEOPLASTICS - ANnNEOPLASTICS, OTHER
AMIFOSTINE BLEOMYCIN COSMEGEN MITOMYCIN
IANnNEOPLASTICS - AROMATASE INHIBITORS, 3RD GENERAnoN
ANASTROZOLE LETROZOLE EXEMESTANE
IANTINEOPLASTICS - ENZVME INHIBITORS
TARCEVA GLEEVEC IR ESSA
!ANnNEOPLASTICS - MOLECULAR TARGET INHIBITORS
TARCEVA IRESSA
AFINITOR JAKAFI
SUTENT TASIGNA
!ANTINEOPLASncs - MONOCLONAL ANnBODIES
HU MIRA CIMZIA
!ANTINEOPLASncs - REnNOIDS TRETINOIN PANRETIN
!ANTIPARAsmcs - ANTHELMINncs PYRIMETHAMINE MEBENDAZOLE
!ANTIPARASmcs - ANTIPROTOZOALS HYDROXYCHLOROQUINE DAPSONE PRJMAQUINE QUINIDINE GLUCONATE COARTEM DARAPRIM
!ANnPARASmcs - PEDICULICIDES/SCABICIDES
PERMETHRIN UNDANE EU RAX STROMECTOL
[ANnPARKINSON AGENTS - ANnCHOLINERGICS
GLEEVEC NEXAVAR TYKERB
TARGRETIN
STROMECTOL
CHLOROQUINE QUALAQUIN FANSIDAR
MALATHION
BENZTROPINE RIVASTIGMINE GALANTAMINE
ANnPARKINSON AGENTS - ANnPARKINSON AGENTS, OTHER
COMTAN STALEVO TASMAR
ANnPARKINSON AGENTS - DOPAMINE AGONISTS
State (or Territory) : ALABAMA Effective Date: 1/ 1/ 2015
DACTINOMYCIN
INLYTA SPRYCEL VOTRJENT
MEFLOQUINE ATOVAQUONE/PROGUANIL MEPRON
NATROBA
ROPINIROLE PRAMIPEXOLE BROMOCRIPTINE APOMORPHINE
!ANnPARKINSON AGENTS - DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS
CARBIDOPNLEVODOPA LO DO SYN
!ANnPARKINSON AGENTS - MONOAMINE ox1DASE B (MAO-B) INHIBITORS
SELEGIUNE AZILECT
!ANnPsvcHoncs - 1ST GENERATION/TYPICAL
CHLORPROMAZINE TRIFLUOPERAZINE LOXAPINE
EHIM ()2014 (800) 311-3446
Print Date: December 24, 2014
HALOPERIDOL THI0R1DAZINE ORAP
www.ehimrx.com
PROCHLORPERAZINE FLUPHENAZINE
THIOTHIXENE PERPHENAZINE
Page 5 of 636
State ( or Territory) : ALABAMA Effective Date : 1/ 1/ 2015
jANTIPSYCHOTICS - 2ND GENERATION/ ATYPICAL R1SPERID0NE CLOZAPINE LATUDA
QUETIAPINE INVEGA
IANTIPSYCHOTICS - TREATMENT-RESISTANT ABILIFY
OLANZAPINE ABILIFY
jANTISPASTICITY AGENTS - ANTISPASTICITY AGENTS
CYCL0BENZAPR1NE BACLOFEN TIZANIDINE
!ANTIVIRALS - ANTl·CYTOMEGALOVIRUS {CMV) AGENTS
GANCICLOVIR VALCYTE
!ANTIVIRALS - ANTIHEPATITIS AGENTS INTRON A PEGASYS RIBAVIRIN EPIVIR HBV COPEGUS TYZEKA
!ANTIVIRALS - ANTIHERPETIC AGENTS ACYCLOVIR DENAVIR
VALACYCLOVIR
RIBAPAK HEPSERA VICTRELIS
FAMCICLOVIR
ZIPRASIDONE SAPHRIS
DANTROLENE
R1BASPHERE BARACLUDE INCIVEK
TRIFLURIDINE
!ANTIVIRALS - ANTI-HIV AGENTS, NON•NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS SUSTIVA ATRJPLA INTELENCE VI RAMU NE RESCRIPTOR
ANTIVIRALS - ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
ZIDOVUDINE COMBIVIR
VIREAD EPZICOM
EPIVIR TRIZIVIR
DIDANOSINE STAVUDINE VIDEX
!ANTIVIRALS - ANTI-HIV AGENTS, OTHER ISENTRESS SELZ ENTRY FUZEON
!ANTIVIRALS - ANTI-HIV AGENTS, PROTEASE INHIBITORS KALETRA PREZISTA REYATAZ APTIVUS CRIXIVAN
INVIRASE
!ANTIVIRALS· ANTI-INFLUENZA AGENTS
VIRACEPT
AMANTADINE TAMI FLU RELENZA
jANXIOL YTICS - ANXIOL YTICS, OTHER
EMTRIVA TRUVADA
LEXIVA NORVIR
BUS PIRONE CHLORDIAZEPOXlDE CHLORDIAZ/CLIDIN MEPROBAMATE
ANXIOLYTICS-SSRIS/SNRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITORS/SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS)
FLUOXETINE FLUVOXAMINE
PAROXETINE
!BIPOLAR AGENTS - BIPOLAR AGENTS, OTHER R1SPERID0NE QUETIAPINE OXCARBAZEPINE ABILIFY
!BIPOLAR AGENTS - MOOD STABIUZERS LITHIUM VALPROATE SODIUM
EHIM 0 2014 (800) 311-34'46 www.ehimrx.com
Print Date: December 24, 2014
SERTRALINE VENLAFAXINE
OLANZAPINE ZIPRASIDONE
LAMOTRIGINE CARBAMAZEPINE
Page 6 of636
••• IU r h at
State ( or Territory) : ALABAMA Effective Date: 1/1/ 2015
!BLOOD GLUCOSE REGULATORS - ANTIDIABETIC AGENTS METFORMIN GLIPIZIDE GLIMEPIRIDE PIOGUTAZONE ACARBOSE NATEGLINIDE GLYBURIDE/ METFORMIN PIOGUTAZONE/ METFORMIN PIOGLITAZI NE/ GUMEPIRIDE BROMOCRIPTINE PRANDIMET JANUVIA JENTADUETO AVANDIA AVANDARYL BYETTA
!BLOOD GLUCOSE REGULATORS- GLYCEMIC AGENTS
GLUCAGON PROGL YCEM
!BLOOD GLUCOSE REGULATORS - INSULINS HUMULIN NOVOLIN R NOVOUN N NOVO LOG HUMALOG LEVE MIR NOVOLOG MIX APIDRA
!BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - ANTICOAGULANTS
WARF ARIN HEPARIN
GLYBURIDE GUPIZIDE/ METFORMIN CHLORPROPAMIDE JANUMET VICTOZA
NOVOLIN 70/ 30 LANTUS
!BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - BLOOD FORMATION MODIFIERS
PROCRIT EPOGEN GRANIX ARANESP
NEUPOGEN NEUMEGA LEU KI NE
!BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - COAGULANTS
CYKLOKAPRON
!BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - PLATELET MODIFYING AGENTS CLOPIDOGREL CILOSTAZOL DIPYRIDAMOLE ANAGRELIDE AGGRENOX EFFIENT XAREL TO PRADAXA
CARDIOVASCULAR AGENTS - ALPHA-ADRENERGIC AGONISTS
CLONIDINE METHYLDOPA METHYLDOPA/HCTZ MIDODRINE
CARDIOVASCULAR AGENTS - ALPHA-ADRENERGIC BLOCKING AGENTS TAMSULOSIN DOXAZOSIN TERAZOSIN PRAZOSI N
'CARDIOVASCULAR AGENTS - ANGIOTENSIN JI RECEPTOR ANTAGONISTS LOSARTAN LOSARTAN/ HCTZ IRBESARTAN EPROSARTAN DIOVAN ATACAND MI CARD IS BENICAR
CARDIOVASCULAR AGENTS - ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
LISINOPRIL USINOPRILJHCTZ RAMIPRIL QUINAPRIL TRANDOLAPRIL PERINDOPRIL
BENAZEPRIL FOSINOPRIL
CAPTOPRIL MOEXIPRIL
!CARDIOVASCULAR AGENTS - ANTIARRHYTHMICS
AMIODARONE SOTALOL
DI SOPYRAMIDE MEXILETINE
FLECAINIDE QUI NIDINE GLUCONATE
PROPAFENONE QUINIDINE SULFATE
TIKOSYN SO RINE
!CARDIOVASCULAR AGENTS - BETA-ADRENERGIC BLOCKING AGENTS
METOPROLOL TARTRATE CARVEDILOL BYSTOUC PINDOLOL
ATENOLOL LABETALOL ACEBUTOLOL
BISOPROLOL METOPROLOL SUCCINATE BETAXOLOL
PROPRANOLOL NADOLOL TIMOLOL
Tla-and lhl data and,cr inbmalion conuiled in la doc:unont(1nlormaonj n O'Mlld by EHlliol koantii1• "9aly prMogod, ccrddontial and propietay inlormation .-l'lllllloaual pr-1)' ol EHILI NI lapr- tandisd>s&n trcugh • ~•)aidiar las llalrlqlftl>ereciportto keep t,e lnlarmatianconlidontal. n. fnbmmoorr.ar not bo ,.-. disclooed. usod - llhd ._ n- a in pal, wll101.010 pri,r ....,con.,tolEHlliol Tlis lnlonnaMi .. b o inlBndod~ farlhlrec,piert--llJt>onzad by EHILl lo - 11. ttyou .. notlhoinllndod redplonl p1o .. no(fy EHILland inmodialoly -, ,t,oo .-.-deRoy t,e lnlcrmation. Ary lNUlhonzod reproducban. lbaoue. acx:ess, use ardOf action n lllar,ce 011 tle infarrnmOl111 A;cdy prohill1ild ancl ~ onlillt EHILl to legal -...,.,...-.anc1damages.
EHIM 0 2014 (800) 311-3446 www.ehimf'l<.com ·
mm II Print Date: December 24, 2014 Page 7 of636
State (or Territory) : ALABAMA Effective Date : 1/1/2015
!CARDIOVASCULAR AGENTS - CALCIUM CHANNEL BLOCKING AGENTS
AMLODIPINE NIFEDIPINE NIMODIPINE
DILTIAZEM FELODIPINE
VERAPAMIL NISOLDIPINE
!CARDIOVASCULAR AGENTS - CARDIOVASCULAR AGENTS, OTHER
NIFEDIPINE ISRADIPINE
PENTOXIFYLUNE EPLERENONE TEKTURNA TEKTURNA HCT
!CARDIOVASCULAR AGENTS - DIUREncs, CARBONIC ANHYDRASE INHIBITORS
ACETAZOLAMIDE METHAZOLAMIDE
!CARDIOVASCULAR AGENTS - DIUREncs, LOOP FUROSEMIDE BUMETANIDE TORSEMIDE EDECRIN
'CARDIOVASCULAR AGENTS - DIUREncs, POTASSIUM-SPARING SPIRONOLACTONE AMILORIDE SPIRINOLACTONE/HCTZ TRIAMTERENE/HCTZ
!CARDIOVASCULAR AGENTS - DIUREncs, THIAZIDE HCTZ CHLORTHAUDONE INDAPAMIDE METOLAZONE CHLOROTHIAZIDE METHYCLOTHIAZIDE
!CARDIOVASCULAR AGENTS - DYSUPIDEMICS, FIBRIC ACID DERIVAnVES FENOFIBRATE FENOFIBRIC ACID
!CARDIOVASCULAR AGENTS - DYSUPIDEMICS, HMG COA REDUCTASE INHIBITORS SIMVASTATIN ATORVASTATIN LOVASTATIN PRAVASTATIN FLUVASTATIN CRESTOR UVALO
'CARDIOVASCULAR AGENTS - DYSUPIDEMICS, OTHER NIACIN CHOLESTYRAMINE COLESTIPOL LOVAZA ZETIA VYTORIN
'CARDIOVASCULAR AGENTS - VASODILATORS, DIRECT-AcnNG ARTERIAL HYDRALAZINE NITROGLYCERIN NITROGLYCERIN
!CARDIOVASCULAR AGENTS - VASODILATORS, DIRECT-ACTING ARTERIAL/VENOUS
JSOSORBIDE MONONITRATE ISOSORBIDE DINITRATE NITROPRUSSIDE
CENTRAL NERVOUS SYSTEM AGENTS - ATIENnON DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES
AMPHETAMINE SALTS DEXTROAMPHETAMINE VYVANSE METHAMPHETAMINE
CENTRAL NERVOUS SYSTEM AGENTS - ATIENnON DEFICIT HYPERACTIVITY DISORDER AGENTS, NON-AMPHETAMINES
METHYLPHENIDATE DEXMETHYLPHENIDATE MODAFINIL STRATTERA
!CENTRAL NERVOUS SYSTEM AGENTS - CENTRAL NERVOUS SYSTEM AGENTS, OTHER AMITRIPTYUNE TRAZODONE CAFFEINE NUEDEXTA
!CENTRAL NERVOUS SYSTEM AGENTS - FIBROMYALGIA AGENTS DULOXETINE LYRICA SAVELLA I CENTRAL NERVOUS SYSTEM AGENTS - MUL nPLE SCLEROSIS AGENTS COPAXONE BETASERON REBIF AMPYRA GILENYA TECFIDERA TYSABRI
EHIM Cl2014 (800) 311-3446 www.ehimrx.com
Print Date: December 24, 2014 Page 8 of 636
State (or Territory} : ALABAMA Effective Date : 1/1/2015
!DENTAL AND ORAL AGENTS • DENTAL AND ORAL AGENTS CHLORHEX1DINE DOXYCYCUNE TRIAMCINOLONE PASTE OROPHARYNGEAL CEVIUMINE KEPIVANCE LU RIDE
!DERMATOLOGICAL AGENTS • DERMATOLOGICAL AGENTS AMMONIUM LACTATE ERYTHROMYCIN ERYTHROMYCIN/BPO PODOFILOX SOLUTION IMIQUIMOD PROTOPIC
BENZOYL PEROXIDE SELENIUM SULFIDE METRONIDAZOLE ADAPALENE SOLARAZE TRffiNOIN
CUNDAMYCIN TOPICAL SODIUM SULFACETAMIDE TAZORAC CALCIPOTRIENE TRffiNOIN SANTYL
UVADEX EXELDERM VE REGEN FINACEA AVITA CLARAVIS OXSORALEN RE GRAN EX PLEXION
!ENZVME REPLACEMENT /MODIFIERS • ENZVME REPLACEMENT /MODIFIERS
ZEN PEP PANCREASE KUVAN ADAGEN CEREZYME
ALDURAZYME CYSTADANE
BUPHENYL CYSTAGON
FABRAZYME MYOZYME NAGLAZYME
!GASTROINTESTINAL AGENTS • ANnSPASMODICS, GASTROINTESTINAL
ATROPINE/DIPHENOXYLATE DICYCLOMINE ATROPINE DONNATAL HYOSCYAMINE
!GASTROINTESnNAL AGENTS - GASTROINTESnNAL AGENTS, OTHER
ATROPINE/DIPHENOXYLATE LACTULOSE LANSOPRAZOLE TRILYTE XENICAL
'GASTROINTESTINAL AGENTS - HISTAMINE (H2) RECEPTOR ANTAGONISTS
RANmDINE FAMOTIDINE NIZATIDINE
!GASTROINTESTINAL AGENTS - IRRITABLE BOWEL SYNDROME AGENTS
DICYCLOMINE PHENOBARB/HYOSC/ ATROP/S COP
!GASTROINTESTINAL AGENTS - LAXAnVES SENNOSIDES PEG 3350 LACTULOSE
!GASTROINTESTINAL AGENTS - PROTECTANTS SUCRALFATE MISOPROSTOL
!GASTROINTESTINAL AGENTS - PROTON PUMP INHIBITORS OMEPRAZOLE PANTOPRAZOLE LANSOPRAZOLE RABEPRAZOLE ZEGERID
'GENITOURINARY AGENTS - ANTISPASMODICS, URINARY OXYBUTYNIN TOLTERODINE TROSPIUM TOVlAZ VESICARE ENABLEX
!GENITOURINARY AGENTS - BENIGN PROSTAnc HYPERTROPHY AGENTS
TAMSULOSIN FINASTERIDE TERAZOSIN PRAZOSIN JALYN
ALFUZOSIN AVODART
'GENITOURINARY AGENTS • GENITOURINARY AGENTS, OTHER PHENAZOPYRIDINE BETHANECHOL BETHANECHOL
PILOCARPINE
AZELEX CUNDAMYCIN/BPO ULESFIA FLUOROURACIL ELIDEL EURAX ZONALON EPIDUO
NEXAVAR CEREDASE ELAPRASE
GL YCOPYRROLATE
URSODIOL
CIMffiDINE
ESOMEPRAZOLE
OXYTROL
DOXAZOSIN RAPAFLO
Tllll-and "'dala-intlrmationCOl'llanld in lhos doc:a.tnenl("1nlomaion1 ••- by EHllol lCCfltals logalf pririeged, -.i and~ infonn"'°"and,a nolo<*JolproponydEHIMllat 11 fl'o4ldld tom iiodowt tn,ugh .-,.nl(s) andlar - M'*l'*a 1ho r_,i1o keep h lnlorrr.*"1 ~ The 1n1ttMa1icc, may notbo repr0$JC9d, cid>sed. u»d - rtiod upon, 11 v,!lolt, or ii Pa\ -lho pnor - CC111W11 d EHIM. Tllll lnlormalion cs also inllonded sololy Jar llo reai-t .-oe.. amorized by EHIM 1D r-..e d. ff you•• notlho l1llnded r9Cipin. please notfy EHIM and mmociallt,, mm II - . otnd ---de~ 1ho lnlcrmalion. Any INUtlorillod reprO<ldo<,, cisdosre, acooss, uso ll'ld,or _,",....,..on lht lnlonnalon Is $l'ldty P'ohl>ilod and may ent,ie EHIM1D logal endJor ~-anddanagn.
'h••lll'I• y l • ntf h "'•••ftd
EHIM ()2014 (800) 311-3446 www.ehimrx.com
Print Date: December 24, 2014 Page 9 of636
State ( or Territory) : ALABAMA Effective Date : 1/ 1/ 2015
!GENITOURINARY AGENTS· PHOSPHATE BINDERS
CALCIUM ACETATE RENVELA RENAGEL
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (ADRENAL) -GLUCOCORTICOIDS/MINERALOCORTICOIDS
HYDROCORTISONE BETAMETHASONE VALERATE BETAMETH DIPROP CLOBETASOL DESONIDE DESOXIMETASONE DIFLORASONE FLUOCINOLONE HYDROCORTISONE BUTYRATE HYDROCORTISONE VALERATE METHYLPREDNISOLONE MOMETASONE ALCLOMETASONE AMCINONIDE AUGMENTED BETAMETHASONE CLOBETASOL E DEXAMETHASONE FLUDROCORTISONE HALOBETASOL PREDNICARBATE CLO BEX CORTISONE SCALACORT
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING {PITUITARY) - HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (PITUITARY)
DESMOPRESSIN CHORIONIC GONADOTROPIN GENOTROPIN SEROSTIM
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (PROSTAGLANDINS) - HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING PROSTAGLANDINS)
ALPROSTADIL
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING {SEX HORMONES/MODIFIERS) -ANABOUC STEROIDS
OXANDROLONE ANADROL
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (SEX HORMONES/MODIFIERS) -ANDROGENS
FIRST-TESTOSTERONE TESTOSTERONE DANAZOL ANDROXY
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (SEX HORMONES/MODIFIERS) -ESTROGENS
CU MARA ACTIVE LL.A ALORA COMBI PATCH
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (SEX HORMONES/MODIFIERS) -PROGESTINS
MEDROXYPROGESTERONE MEDROXYPRO ACETATE MEGESTROL PROGESTERONE MICRONIZED
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING {SEX HORMONES/MODIFIERS) -SELECTIVE ESTROGEN RECEPTOR MODIFYING AGENTS
EVISTA
HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (THYROID) - HORMONAL AGENTS, STIMULANT /REPLACEMENT /MODIFYING (THYROID)
LEVOTHYROXI NE LIOTHYRONINE SYNTHROID
!HORMONAL AGENTS, SUPPRESSANT (ADRENAL) - HORMONAL AGENTS, SUPPRESSANT (ADRENAL)
LYSODREN
HORMONALAGENTS,SUPPRESSANT(PARATHYROID)-HORMONALAGENTS,SUPPRESSANT (PARATHYROID)
SENSIPAR
!HORMONAL AGENTS, SUPPRESSANT (PITUITARY) - HORMONAL AGENTS, SUPPRESSANT (PITUITARY}
CABERGOUNE SOMAVERT SANDOSTATIN
OCTREOTIDE SYNAREL
LEUPROU DE TRE LST AR LA
SOMATUUNE EUGARD
!HORMONAL AGENTS, SUPPRESSANT (SEX HORMONES/MODIFIERS} - ANTIANDROGENS
BICALUTAMIDE FLUTAMIDE NI LANDRON XTANDI 2YTIGA
'HORMONAL AGENTS, SUPPRESSANT (THYROID) - ANTITHYROID AGENTS
METHIMAZOLE PROPYLTHIOURACIL
EHIM C>2014 (800) 311-3446 www.ehimrx.com
Print Date: December 24, 2014 Page 10 of 636